Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Reiter, E; Greinix, HT; Brugger, S; Keil, F; Rabitsch, W; Mannhalter, C; Schwarzinger, I; Höcker, P; Fischer, G; Dieckmann, K; Hinterberger, W; Linkesch, W; Schneider, B; Lechner, K; Kalhs, P.
Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Bone Marrow Transplant. 1998; 22 Suppl 4(8):S86-S88
Web of Science
PubMed
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Between January 1983 and July 1997, 83 patients (35 female, 48 male) with a median age of 37 (19-57) years with chronic myelogenous leukemia (CML) were admitted for bone marrow transplantation (BMT) at the University hospital of Vienna. Fifty-six patients were in chronic phase, 17 in accelerated and 10 had blast crisis. Marrow donors were: HLA-identical siblings in 62 patients, 2-antigen mismatched related donor in 2, HLA-identical unrelated donors (MUD) in 17 and 1-antigen mismatched unrelated donor in 2 patients. The median time from diagnosis to BMT was 22 (2-91) months. Conditioning therapy consisted of cyclophosphamide (CY) and total body irradiation or CY and busulfan. For graft-versus-host disease (GVHD) prophylaxis methotrexate (MTX) alone, MTX and cyclosporine A (CSA), CSA alone or CSA and methylprednisone were given. Durable engraftment was documented in 75 of 77 patients (97%). As of July 31, 1997 48 patients are alive (58%), 36 (56%) after sibling transplantation with a median observation time of 77 months and 12 (63%) after MUD transplantation with a median observation time of 13 months. Overall survival for patients in chronic phase (CP) at time of BMT is 64%, 53% for patients in acceleration and 30% for patients in blast crisis (BC). Disease-free survival (DFS) after sibling BMT and unrelated donor transplantation is 53% and 58%, respectively. Ten patients (12%) experienced relapse of CML. Transplant-related mortality was 33% after sibling and 32% after MUD transplantation. Thus, sibling and unrelated donor BMT offer high cure rates with acceptable toxicity to patients with CML.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Female -
- Follow-Up Studies -
- Hematopoietic Stem Cell Transplantation -
- Histocompatibility Testing -
- Humans -
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
- Male -
- Middle Aged -
- Treatment Outcome -